Cargando…
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
BACKGROUND: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro. MATERIALS & METHODS: Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysi...
Autores principales: | Horga, Arantxa, Kuritzkes, Daniel R., Kowalczyk, John J., Pietropaolo, Keith, Belanger, Bruce, Lin, Kai, Perkins, Kristen, Hammond, Janet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308776/ http://dx.doi.org/10.2217/fvl-2023-0064 |
Ejemplares similares
-
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
por: Horga, Arantxa, et al.
Publicado: (2023) -
A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)
por: Boffito, Marta, et al.
Publicado: (2023) -
Type II taste cells participate in mucosal immune surveillance
por: Qin, Yumei, et al.
Publicado: (2023) -
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
por: Monteiro, Cecilia, et al.
Publicado: (2023) -
Participation in paediatric cancer studies: timing and approach to recruitment
por: Heiden, Tamika L, et al.
Publicado: (2013)